Received May 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (NO BRAND NAME) | UNKNOWN MANUFACTURER | 1 | UNK | — |
neurologically compromised; This non-serious case was reported by a consumer via interactive digital media and described the occurrence of neurological disorder nos in a specified number of patients who received Herpes zoster (Shingles vaccine) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced neurological disorder nos (Verbatim: neurologically compromised). Shingles vaccine was discontinued. The outcome of the neurological disorder nos was resolved (duration 2 weeks). It was unknown if the reporter considered the neurological disorder nos to be related to Shingles vaccine. It was unknown if the company considered the neurological disorder nos to be related to Shingles vaccine. Additional Information: GSK Receipt Date: 22-APR-2025 This case was reported by a consumer via interactive digital media. The reporter reported that these comments would drive reporter to the vaccination but 2 of reporter best friends had horrible reactions to the vaccination, that being neurologically compromised for about 2 weeks. It was bad, one phoned her doctor and said do not take the second vaccination.